U.S. Somatostatin Analogs Market

The U.S. Somatostatin Analogs Market is valued at USD 2.5 Billion in 2023 and is projected to reach a value of USD 4.78 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 7.5% between 2024 and 2032.

The U.S. Somatostatin Analogs market is experiencing grow steadily, driven by continued advancements in drug formulations, a rise in target patient populations, and increasing awareness among healthcare providers and patients.

Type Overview

​The Type segment is divided into Octreotide, Lanreotide, Pasireotide.

Octreotide: The octreotide category in the U.S market is significant due to its extensive use in managing conditions like acromegaly, neuroendocrine tumors (NETs), and severe cases of diarrhea associated with carcinoid syndrome. For instance, January 2024, Novartis presented data from the Phase III NETTER-2 trial showing that Lutathera® (lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose octreotide LAR alone1. Data were presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.

Lanreotide: The lanreotide category is particularly use for treating acromegaly and certain types of neuroendocrine tumors (NETs). Lanreotide has demonstrated efficacy in delaying tumor progression in patients with NETs, expanding its relevance beyond symptom management to include disease control in oncology settings. The demand for lanreotide is supported by increasing NET incidence rates and rising awareness of effective treatment options.

Pasireotide: The pasierotide is specialized use in treating conditions that are less responsive to other somatostatin analogs, such as Cushing's disease and acromegaly. Pasireotide, marketed by Novartis under the brand name Signifor, has a unique binding profile that allows it to act on multiple somatostatin receptor subtypes, making it particularly effective in controlling ACTH (adrenocorticotropic hormone) secretion in patients with Cushing's disease who cannot undergo surgery or have experienced surgery failure.

Application Overview

The Application segment is divided into Acromegaly, Neuroendocrine Tumors (NETs), Others.

Acromegaly: Acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (GH) and overproduction of insulin-like growth factor I (IGF-I). Medical therapies, including the somatostatin receptor ligand (SRL) pasireotide, are frequently used to restore biochemical control.

Neuroendocrine Tumors (NETs): The neuroendocrine tumors can develop in various organs, most commonly in the gastrointestinal tract, pancreas, and lungs. For instance, in September 2024, Ipsen announced today final data from the CABINET Phase III trial investigating Cabometyx® (cabozantinib) versus placebo in people living with advanced pancreatic neuroendocrine tumors (pNETs) or advanced extra-pancreatic neuroendocrine tumors (epNETs) whose disease had progressed after prior systemic therapy. These data demonstrated a statistically significant reduction in the risk of disease progression or death for Cabometyx versus placebo of 77% (hazard ratio (HR) 0.23) and 62% (HR 0.38) for people living with advanced pNETs and epNETs.

Regional Overview

The U.S. Somatostatin Analogs market is driven by increasing prevalence of neuroendocrine tumors (NETs), acromegaly, and other hormone-related disorders. For instance, in April 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.

Key Trends

• Shift Toward Long-Acting Formulations: There is a growing preference for long-acting somatostatin analogs, like octreotide LAR and lanreotide, which offer monthly dosing options
• Expansion of Indications: Somatostatin analogs are increasingly being explored for additional therapeutic applications beyond traditional uses in neuroendocrine tumors (NETs) and acromegaly
• Focus on Personalized Medicine: There is a trend toward personalized and targeted treatment approaches, aiming to match specific somatostatin analogs to individual patient needs based on receptor profiles and disease characteristics

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Advancements in Diagnostic Techniques

Advancements in diagnostic techniques are significantly impacting the market by enabling earlier and more accurate detection of neuroendocrine tumors (NETs), acromegaly, and other hormone-related disorders. Enhanced imaging modalities, such as positron emission tomography (PET) combined with computed tomography (CT) and magnetic resonance imaging (MRI), allow for more precise visualization of NETs, often identifying smaller or otherwise undetectable lesions. Additionally, improved blood tests and biomarker assays facilitate early detection and monitoring of hormone levels, enabling healthcare providers to diagnose and manage conditions like acromegaly more effectively.

Increasing Patient and Physician Awareness

As knowledge about rare hormone-related disorders like neuroendocrine tumors (NETs) and acromegaly expands, both patients and healthcare providers are becoming more aware of the symptoms, treatment options, and the benefits of somatostatin analogs in managing these conditions. Physicians, especially specialists in endocrinology and oncology, are better informed about the latest therapies, including long-acting somatostatin analogs like octreotide and lanreotide, which improve patient convenience and adherence. Enhanced awareness helps with earlier diagnosis and timely treatment initiation, which are crucial for managing chronic conditions that require long-term hormone regulation.

Competitive Landscape

The U.S. Somatostatin Analogs market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major players are Novartis AG, Ipsen, Sun pharmaceuticals, Teva Pharmaceuticals, and Others. With the growing prevalence of endocrine and neuroendocrine disorders, the market remains competitive, with companies vying for market share through product differentiation, pricing strategies, and expanding therapeutic indications.

Recent Market Developments

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

• In October 2024, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin®1 LAR Depot, in the United States.

The global U.S. Somatostatin Analogs market can be categorized as Type, End-Use and Region.